EUVIMEDEUVIMED entdecken
Crossref

NeoMS: Mass Spectrometry-Based Method for Uncovering Mutated MHC-I Neoantigens

Shaokai Wang, Ming Zhu, Bin Ma

IEEE Transactions on Computational Biology and Bioinformatics · 2025

DOI: 10.1109/tcbb.2024.3447746 ↗

Kurz gefasst

Fachartikel in der Zeitschrift IEEE Transactions on Computational Biology and Bioinformatics, 2025. Verfasst von Shaokai Wang und 2 weiteren Autor:innen. Hauptthemen laut MEDLINE: Mass Spectrometry, Antigens, Neoplasm, Histocompatibility Antigens Class I, Computational Biology. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 38 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Major Histocompatibility Complex (MHC) molecules play a critical role in the immune system by presenting peptides on the cell surface for recognition by T-cells. Tumor cells often produce MHC peptides with amino acid mutations, known as neoantigens, which evade T-cell recognition, leading to rapid tumor growth. In immunotherapies such as TCR-T and CAR-T, identifying these mutated MHC peptide sequences is crucial. Current mass spectrometry-based peptide identification methods primarily rely on database searching, which fails to detect mutated peptides not present in human databases. In this paper, we propose a novel workflow called NeoMS, designed to efficiently identify both non-mutated and mutated MHC-I peptides from mass spectrometry data. NeoMS utilizes a tagging algorithm to generate an expanded sequence database that includes potential mutated proteins for each sample. Furthermore, it employs a machine learning-based scoring function for each peptide-spectrum match (PSM) to maximize search sensitivity. Finally, a rigorous target-decoy approach is implemented to control the false discovery rates (FDR) of the peptides with and without mutations separately. Experimental results for regular peptides demonstrate that NeoMS outperforms four benchmark methods. For mutated peptides, NeoMS successfully identifies hundreds of high-quality mutated peptides in a melanoma-associated sample, with their validity confirmed by further studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mass SpectrometryAntigens, NeoplasmHistocompatibility Antigens Class IComputational BiologyHumansMutationAlgorithmsDatabases, ProteinPeptides

Substanzen

Antigens, NeoplasmHistocompatibility Antigens Class IPeptides

Zitieren

APA

Wang, S., Zhu, M., & Ma, B. (2025). NeoMS: Mass Spectrometry-Based Method for Uncovering Mutated MHC-I Neoantigens. IEEE Transactions on Computational Biology and Bioinformatics. https://doi.org/10.1109/tcbb.2024.3447746

Vancouver

Wang S, Zhu M, Ma B. NeoMS: Mass Spectrometry-Based Method for Uncovering Mutated MHC-I Neoantigens. IEEE Transactions on Computational Biology and Bioinformatics. 2025. doi:10.1109/tcbb.2024.3447746

BibTeX
@article{Wang2025,
  author = {Wang, Shaokai and Zhu, Ming and Ma, Bin},
  title = {NeoMS: Mass Spectrometry-Based Method for Uncovering Mutated MHC-I Neoantigens},
  journal = {IEEE Transactions on Computational Biology and Bioinformatics},
  year = {2025},
  doi = {10.1109/tcbb.2024.3447746}
}
Kostenlos starten →